Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
This editorial refers to ‘Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF’, by J.P. Curtain et al., doi:10.1093/eurheartj/ehab560. Experimental design and major conclusions. Sodium–glucose co-transporter 2 inhibitors (SGLT2is), such as empagliflozin and dapagliflozin, have been developed as antidiabetic drugs that promote urinary excretion of glucose to improve glycaemic control.1 Surprisingly, recent large-scale cardiovascular (CV) safety trials demonstrate that SGLT2is significantly reduce the incidence of heart failure (HF) by 30–40% in diabetes patients.2–6 Furthermore, results from the EMPEROR-Reduced and DAPA-HF trials7–9 demonstrate that the marked cardioprotective effects of the SGLT2is are preserved in the absence of diabetes, suggesting protective mechanisms that are independent of improved glycaemic control. While the SGLT2i-mediated reduction in HF has understandably received the majority of attention, other signals such as reduction in sudden cardiac death (SCD) were also detected in these CV safety trials. These additional findings raise the possibility that SGLT2is may also possess an unexpected beneficial effect against ventricular arrhythmias which are one of the principal causes of SCD in patients with HF. Therefore, it is important to decode the trial data regarding any potential effects of the SGLTis on the incidence of ventricular arrhythmias. In this issue of the European Heart Journal, Curtain et al. directly address this notion by performing a post-hoc analysis of the DAPA-HF trial data to examine the incidence of adverse events reporting of ventricular arrhythmias, resuscitated cardiac arrest, and sudden death in the dapagliflozin and placebo trial cohorts.10 The DAPA-HF data set8 is ideal for such an analysis on HF patients with reduced ejection fraction (HFrEF) as data from 4744 patients were available where adverse events were logged by investigators. The authors employed Cox proportional hazard regression models to perform sensitivity analyses on variables including age, sex, presence of ischaemic disease, implantable cardioverter defibrillators (ICDs), N-terminal probrain natriuretic peptide (NT-proBNP) status, and hypertension. Findings from this study indicate that dapagliflozin, when added to standard HF pharmacotherapy, reduced the composite outcome (ventricular arrhythmias, resuscitated cardiac arrest, or sudden death) to 5.9%, vs. 7.4% in the placebo group that received standard HF pharmacotherapy alone, resulting in a hazard ratio (HR) of 0.79 (P = 0.037). Furthermore, the authors also observed that this reduction in the composite outcome was further decreased in patients with below median NT-proBNP levels (HR = 0.58) when compared with patients with above-median NT-proBNP levels (HR = 0.83). Taken together, these results provide evidence for a protective effect of dapagliflozin against life-threatening electrical disturbances and that dapagliflozin may bestow additional protection in patients who were in the earlier stages of HFrEF at the time of enrolment, as defined by lower NT-proBNP levels. The strongest separation of the HR values was observed >9 months post-randomization, suggesting that the observed beneficial effects of dapagliflozin require time to develop and may involve cellular mechanisms that slow the progression of HFrEF. In this regard, there have been several pre-clinical studies that have provided insights as to precisely how the SGLT2is might afford protection against HF and cardiac arrhythmias. These include a reduction in the priming and activation of the cardiac NLRP3 (nucleotide-binding domain-like receptor protein 3) inflammasome,11 , 12 inhibition of the late component of the cardiac sodium current,12 and the sodium–hydrogen exchanger.13 SGLT2is may also confer protection against structural (and perhaps electrical) remodelling through beneficial haemodynamic and metabolic alterations, as well as changes in sympathetic and parasympathetic tone. The use of the DAPA-HF trial data also supports the notion that the SGLT2is are of direct cardiovascular benefit for the tested composite outcome in patients without cardiac dysfunction resulting from diabetes. This study adds further evidence to the emerging concept that the SGLT2is possess a direct protective effect on the heart. Whether or not the SGLT2is reduced the composite outcome primarily as a result of a reduction in ionic disturbances that are associated with HF,14 , 15 and the subsequent decrease of a proarrhythmic electrophysiological substrate, or secondary to the beneficial effects of SGLT2is on structural remodelling, remains to be determined in future studies. In this respect, Curtain et al. show that the observed reduction in composite outcome was not observed in patients with ICDs, suggesting that the SGLT2is may directly influence the synchronicity of cardiac excitation. However, it may be the case that patients with ICDs are at
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nephropathy caused by diabetes is a leading cause of CKD globally, and screening patients with diabetes for CKD is recommended at least annually.676,677”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [676]
Citations
Cites
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Cardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Zannad, F., Ferreira, J. P., Pocock, S. J., Anker, S. D., Butler, J., Filippatos, G., Brueckmann, M., Ofstad, A. P., Pfarr, E., Jamal, W., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31824-9 · Cited by 1,408
Kosiborod, M., Cavender, M. A., Fu, A. Z., Wilding, J. P., Khunti, K., Holl, R. W., Norhammar, A., Birkeland, K. I., Jørgensen, M. E., Thuresson, M., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.029190 · Cited by 813
Uthman, L., Baartscheer, A., Bleijlevens, B., Schumacher, C. A., Fiolet, J. W. T., Koeman, A., Jancev, M., Hollmann, M. W., Weber, N. C., Coronel, R., et al. (2018) · Diabetologia · doi:10.1007/s00125-017-4509-7 · Cited by 610
Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus
Kato, E. T., Silverman, M. G., Mosenzon, O., Zelniker, T. A., Cahn, A., Furtado, R. H. M., Kuder, J., Murphy, S. A., Bhatt, D. L., Leiter, L. A., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.040130 · Cited by 557
An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus
Hsia, D. S., Grove, O., & Cefalu, W. T. (2017) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000311 · Cited by 508
Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program
Rådholm, K., Figtree, G., Perkovic, V., Solomon, S. D., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Barrett, T. D., Shaw, W., Desai, M., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.034222 · Cited by 488
Lytvyn, Y., Bjornstad, P., Udell, J. A., Lovshin, J. A., & Cherney, D. Z. I. (2017) · Circulation · doi:10.1161/circulationaha.117.030012 · Cited by 459
Fitchett, D., Inzucchi, S. E., Cannon, C. P., McGuire, D. K., Scirica, B. M., Johansen, O. E., Sambevski, S., Kaspers, S., Pfarr, E., George, J. T., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.037778 · Cited by 351
Research works printed but not linked: 1
- 2021, Eur Heart J
Cited by
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Dyck, J. R. B., Sossalla, S., Hamdani, N., Coronel, R., Weber, N. C., Light, P. E., & Zuurbier, C. J. (2022) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2022.03.005 · Cited by 169
Self-citationArmillotta, M., Angeli, F., Paolisso, P., Belmonte, M., Raschi, E., Dalmazi, G. D., Amicone, S., Canton, L., Fedele, D., Suma, N., et al. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108861 · Cited by 84
Andelová, K. O., Bačová, B. S., Sýkora, M., Hlivák, P., Barančík, M., & Tribulová, N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031416 · Cited by 58
Sodium-glucose cotransporter type 2 inhibitors and cardiac arrhythmias
Manolis, A. S., Manolis, T. A., Melita, H., & Manolis, A. S. (2022) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2022.04.003 · Cited by 33
Metadata
- Authors
- Light, P. E.
- Affiliations
- University of Alberta (CA)
- Corresponding author
- Light, Peter E
- ORCID
- Light, Peter E
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-08-27
- Volume
- 42
- Issue
- 36
- Pages
- 3739-3740
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- PMC
- PMC8455342
- OpenAlex
- W3193981514
- Cited by
- 28
- References
- 16
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 4 · 2023: 6 · 2022: 10 · 2021: 2
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- European Heart Journal (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research
- Dr Rod Eidem Diabetes Research Fund
- Dr Charles A. Allard Chair in Diabetes Research
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- SGLT2 inhibitors, dapagliflozin, ventricular arrhythmias, heart failure with reduced ejection fraction, sudden cardiac death, resuscitated cardiac arrest, DAPA-HF trial, EMPEROR-Reduced trial
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Arrhythmias, Cardiac, Heart Failure, Humans, Hypoglycemic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure. https://app.cochat.ai/papers/10.1093/eurheartj/ehab563
- The paper
- Light, P. E. (2021). Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure. European Heart Journal. https://doi.org/10.1093/eurheartj/ehab563
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.